Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Nephrology | 26 | 2025 | 270 | 7.710 |
Why?
|
Kidney Diseases | 29 | 2025 | 2100 | 6.900 |
Why?
|
Renal Dialysis | 42 | 2024 | 1791 | 5.000 |
Why?
|
Kidney Failure, Chronic | 30 | 2024 | 2496 | 4.410 |
Why?
|
Peritoneal Dialysis | 10 | 2024 | 161 | 3.640 |
Why?
|
Renal Insufficiency, Chronic | 21 | 2024 | 2298 | 3.360 |
Why?
|
Nephrons | 10 | 2023 | 166 | 2.460 |
Why?
|
Kidney | 27 | 2024 | 7064 | 2.190 |
Why?
|
Renal Replacement Therapy | 9 | 2024 | 282 | 2.170 |
Why?
|
Acute Kidney Injury | 22 | 2024 | 1942 | 2.140 |
Why?
|
Health Services Accessibility | 15 | 2024 | 5520 | 1.740 |
Why?
|
Premature Birth | 4 | 2023 | 1829 | 1.220 |
Why?
|
Renal Insufficiency | 6 | 2024 | 812 | 1.170 |
Why?
|
Hypertension | 11 | 2024 | 8616 | 1.130 |
Why?
|
Healthcare Disparities | 6 | 2024 | 3415 | 1.050 |
Why?
|
Hemodialysis, Home | 2 | 2024 | 21 | 1.020 |
Why?
|
Birth Weight | 6 | 2019 | 2121 | 0.980 |
Why?
|
Fetal Development | 3 | 2019 | 779 | 0.950 |
Why?
|
Longevity | 2 | 2023 | 1077 | 0.950 |
Why?
|
Ethics, Research | 4 | 2024 | 178 | 0.930 |
Why?
|
Kidney Transplantation | 13 | 2024 | 4262 | 0.920 |
Why?
|
Medicine, Traditional | 3 | 2012 | 89 | 0.900 |
Why?
|
Shiga-Toxigenic Escherichia coli | 1 | 2023 | 26 | 0.890 |
Why?
|
Hemolytic-Uremic Syndrome | 1 | 2023 | 106 | 0.860 |
Why?
|
Altruism | 1 | 2024 | 211 | 0.810 |
Why?
|
Disasters | 8 | 2024 | 521 | 0.810 |
Why?
|
Glomerular Filtration Rate | 8 | 2023 | 2227 | 0.800 |
Why?
|
Developing Countries | 15 | 2024 | 2910 | 0.770 |
Why?
|
Health Resources | 7 | 2024 | 950 | 0.770 |
Why?
|
Health Care Rationing | 2 | 2021 | 435 | 0.710 |
Why?
|
Humans | 139 | 2025 | 768166 | 0.710 |
Why?
|
Infant, Low Birth Weight | 6 | 2017 | 871 | 0.690 |
Why?
|
Escherichia coli Infections | 1 | 2023 | 524 | 0.670 |
Why?
|
Medicine, African Traditional | 3 | 2005 | 31 | 0.660 |
Why?
|
Africa South of the Sahara | 5 | 2022 | 752 | 0.630 |
Why?
|
Voice | 1 | 2022 | 268 | 0.630 |
Why?
|
Social Responsibility | 2 | 2021 | 382 | 0.610 |
Why?
|
Plant Preparations | 2 | 2012 | 94 | 0.570 |
Why?
|
Conservation of Natural Resources | 1 | 2018 | 209 | 0.510 |
Why?
|
Health Status Disparities | 2 | 2024 | 1885 | 0.490 |
Why?
|
Transients and Migrants | 1 | 2017 | 170 | 0.480 |
Why?
|
Stromal Cells | 1 | 2020 | 1336 | 0.450 |
Why?
|
Delivery of Health Care | 8 | 2024 | 5367 | 0.450 |
Why?
|
Refugees | 2 | 2023 | 615 | 0.450 |
Why?
|
Pre-Eclampsia | 1 | 2023 | 1255 | 0.450 |
Why?
|
Infant, Small for Gestational Age | 1 | 2016 | 468 | 0.430 |
Why?
|
Gestational Age | 3 | 2017 | 3621 | 0.430 |
Why?
|
Disease Progression | 7 | 2025 | 13671 | 0.430 |
Why?
|
Epidemics | 1 | 2019 | 517 | 0.430 |
Why?
|
Goals | 1 | 2018 | 717 | 0.410 |
Why?
|
Risk Factors | 19 | 2025 | 74944 | 0.400 |
Why?
|
Pandemics | 10 | 2024 | 8748 | 0.390 |
Why?
|
Arteriovenous Shunt, Surgical | 3 | 2024 | 291 | 0.390 |
Why?
|
Health Expenditures | 5 | 2020 | 2389 | 0.390 |
Why?
|
Health Priorities | 3 | 2024 | 380 | 0.390 |
Why?
|
Living Donors | 3 | 2015 | 647 | 0.370 |
Why?
|
Martial Arts | 1 | 2011 | 29 | 0.370 |
Why?
|
South Africa | 10 | 2024 | 1873 | 0.350 |
Why?
|
Infant, Newborn | 14 | 2024 | 26422 | 0.350 |
Why?
|
Self Medication | 1 | 2011 | 115 | 0.350 |
Why?
|
Quality of Health Care | 3 | 2023 | 4310 | 0.340 |
Why?
|
Acute-Phase Reaction | 2 | 2010 | 91 | 0.340 |
Why?
|
Chloride Channels | 3 | 2000 | 221 | 0.330 |
Why?
|
Disease Management | 2 | 2017 | 2536 | 0.330 |
Why?
|
Aging, Premature | 1 | 2009 | 44 | 0.330 |
Why?
|
Oncostatin M Receptor beta Subunit | 1 | 2009 | 4 | 0.330 |
Why?
|
Oncostatin M | 1 | 2009 | 42 | 0.320 |
Why?
|
Child Welfare | 1 | 2013 | 523 | 0.320 |
Why?
|
Malnutrition | 1 | 2015 | 632 | 0.300 |
Why?
|
Africa | 3 | 2024 | 725 | 0.300 |
Why?
|
Complementary Therapies | 1 | 2012 | 487 | 0.300 |
Why?
|
Biomedical Research | 2 | 2021 | 3463 | 0.290 |
Why?
|
Child | 21 | 2024 | 80917 | 0.290 |
Why?
|
Tendon Injuries | 1 | 2011 | 329 | 0.280 |
Why?
|
Decision Making | 2 | 2020 | 3953 | 0.280 |
Why?
|
Prenatal Exposure Delayed Effects | 2 | 2019 | 2538 | 0.280 |
Why?
|
Kidney Tubules | 1 | 2009 | 454 | 0.270 |
Why?
|
Endocarditis, Bacterial | 1 | 2011 | 436 | 0.270 |
Why?
|
Switzerland | 2 | 2024 | 323 | 0.260 |
Why?
|
Physicians | 3 | 2023 | 4598 | 0.260 |
Why?
|
Human Growth Hormone | 1 | 2011 | 651 | 0.260 |
Why?
|
Adaptation, Physiological | 1 | 2012 | 1312 | 0.250 |
Why?
|
Internationality | 2 | 2020 | 1008 | 0.240 |
Why?
|
Phosphines | 1 | 2024 | 18 | 0.240 |
Why?
|
Red Cross | 1 | 2024 | 12 | 0.240 |
Why?
|
Glomerulonephritis | 2 | 2024 | 333 | 0.230 |
Why?
|
Malaria | 2 | 2024 | 1249 | 0.220 |
Why?
|
Animals, Newborn | 1 | 2009 | 2678 | 0.220 |
Why?
|
Water-Electrolyte Imbalance | 1 | 2005 | 111 | 0.220 |
Why?
|
Complement Inactivating Agents | 1 | 2023 | 53 | 0.220 |
Why?
|
Androgens | 1 | 2011 | 1281 | 0.220 |
Why?
|
Phytotherapy | 2 | 2003 | 298 | 0.210 |
Why?
|
Uremia | 1 | 2024 | 202 | 0.210 |
Why?
|
Adult | 22 | 2024 | 223646 | 0.200 |
Why?
|
Aloe | 1 | 2002 | 2 | 0.200 |
Why?
|
Poverty | 3 | 2020 | 2720 | 0.200 |
Why?
|
Critical Care | 5 | 2024 | 2715 | 0.180 |
Why?
|
Europe | 4 | 2024 | 3436 | 0.180 |
Why?
|
Pregnancy | 7 | 2024 | 30256 | 0.180 |
Why?
|
Consensus | 3 | 2014 | 3212 | 0.170 |
Why?
|
Dietary Proteins | 2 | 2008 | 960 | 0.170 |
Why?
|
Catastrophic Illness | 1 | 2020 | 60 | 0.170 |
Why?
|
Climate Change | 2 | 2024 | 509 | 0.170 |
Why?
|
Kidney Calculi | 1 | 2004 | 458 | 0.170 |
Why?
|
Carbon | 1 | 2023 | 673 | 0.170 |
Why?
|
Ethics Committees, Research | 1 | 2021 | 196 | 0.170 |
Why?
|
Female | 29 | 2024 | 397192 | 0.170 |
Why?
|
Nephritis, Interstitial | 1 | 2021 | 158 | 0.160 |
Why?
|
Central America | 1 | 2019 | 69 | 0.160 |
Why?
|
Masks | 1 | 2022 | 214 | 0.160 |
Why?
|
Morals | 1 | 2022 | 288 | 0.160 |
Why?
|
Streptococcal Infections | 1 | 2024 | 619 | 0.160 |
Why?
|
Sri Lanka | 1 | 2019 | 93 | 0.160 |
Why?
|
Critical Illness | 4 | 2020 | 2756 | 0.160 |
Why?
|
Policy | 1 | 2023 | 513 | 0.160 |
Why?
|
Relief Work | 2 | 2010 | 131 | 0.160 |
Why?
|
Male | 31 | 2024 | 364719 | 0.160 |
Why?
|
Early Diagnosis | 2 | 2020 | 1194 | 0.160 |
Why?
|
Kidney Cortex | 1 | 1998 | 168 | 0.160 |
Why?
|
Physician-Patient Relations | 1 | 2012 | 3269 | 0.160 |
Why?
|
Long-Term Care | 1 | 2023 | 631 | 0.150 |
Why?
|
Organ Size | 2 | 2016 | 2267 | 0.150 |
Why?
|
Thromboembolism | 1 | 2024 | 1004 | 0.150 |
Why?
|
Education | 1 | 2020 | 533 | 0.150 |
Why?
|
Informed Consent | 1 | 2024 | 1010 | 0.140 |
Why?
|
Earthquakes | 2 | 2010 | 192 | 0.140 |
Why?
|
Health Planning | 1 | 2019 | 233 | 0.140 |
Why?
|
Wounds and Injuries | 3 | 2014 | 2517 | 0.140 |
Why?
|
Developed Countries | 4 | 2024 | 451 | 0.140 |
Why?
|
Conflict of Interest | 1 | 2022 | 556 | 0.140 |
Why?
|
Research Support as Topic | 1 | 2021 | 696 | 0.140 |
Why?
|
Hypertension, Renal | 1 | 2017 | 135 | 0.140 |
Why?
|
Blood Pressure | 3 | 2019 | 8543 | 0.140 |
Why?
|
Cystatin C | 2 | 2016 | 272 | 0.140 |
Why?
|
Social Justice | 1 | 2020 | 486 | 0.130 |
Why?
|
Sex Factors | 3 | 2022 | 10632 | 0.130 |
Why?
|
Term Birth | 1 | 2016 | 140 | 0.130 |
Why?
|
Health Policy | 4 | 2024 | 2698 | 0.130 |
Why?
|
Ethics, Medical | 1 | 2021 | 785 | 0.130 |
Why?
|
Malaria, Falciparum | 1 | 2024 | 1077 | 0.120 |
Why?
|
Infant, Premature | 2 | 2017 | 2124 | 0.120 |
Why?
|
Biological Specimen Banks | 1 | 2021 | 788 | 0.120 |
Why?
|
Health Planning Organizations | 1 | 2014 | 13 | 0.120 |
Why?
|
Research Design | 2 | 2024 | 6211 | 0.120 |
Why?
|
Hospitals, Pediatric | 1 | 2024 | 1876 | 0.120 |
Why?
|
Primary Graft Dysfunction | 1 | 2015 | 112 | 0.120 |
Why?
|
Violence | 1 | 2020 | 936 | 0.110 |
Why?
|
Disease Outbreaks | 1 | 2024 | 1761 | 0.110 |
Why?
|
Risk Reduction Behavior | 1 | 2020 | 1119 | 0.110 |
Why?
|
Cost-Benefit Analysis | 2 | 2024 | 5536 | 0.110 |
Why?
|
Triage | 1 | 2020 | 997 | 0.110 |
Why?
|
Maternal Age | 1 | 2016 | 805 | 0.110 |
Why?
|
Cardiovascular Diseases | 2 | 2009 | 15662 | 0.110 |
Why?
|
Child, Preschool | 8 | 2024 | 42669 | 0.110 |
Why?
|
Socioeconomic Factors | 2 | 2024 | 7852 | 0.110 |
Why?
|
Maternal Welfare | 1 | 2013 | 113 | 0.100 |
Why?
|
Herb-Drug Interactions | 1 | 2012 | 8 | 0.100 |
Why?
|
Health Services Needs and Demand | 2 | 2017 | 1406 | 0.100 |
Why?
|
Morbidity | 1 | 2018 | 1755 | 0.100 |
Why?
|
Graft Survival | 3 | 2021 | 3887 | 0.100 |
Why?
|
Patient Care Team | 1 | 2023 | 2523 | 0.100 |
Why?
|
Capacity Building | 1 | 2014 | 265 | 0.100 |
Why?
|
Rats | 4 | 2020 | 23760 | 0.100 |
Why?
|
Adolescent | 11 | 2024 | 89169 | 0.100 |
Why?
|
Creatinine | 2 | 2015 | 1918 | 0.100 |
Why?
|
Urea | 2 | 2024 | 448 | 0.100 |
Why?
|
Proteinuria | 2 | 2013 | 611 | 0.090 |
Why?
|
Asia | 2 | 2024 | 629 | 0.090 |
Why?
|
Drug Contamination | 1 | 2012 | 151 | 0.090 |
Why?
|
Renal Artery | 1 | 2012 | 354 | 0.090 |
Why?
|
Delayed Graft Function | 1 | 2011 | 50 | 0.090 |
Why?
|
Renal Colic | 1 | 2011 | 27 | 0.090 |
Why?
|
Crush Syndrome | 1 | 2010 | 8 | 0.090 |
Why?
|
Shc Signaling Adaptor Proteins | 1 | 2009 | 46 | 0.090 |
Why?
|
Hyperparathyroidism, Secondary | 1 | 2011 | 124 | 0.090 |
Why?
|
Body Height | 1 | 2016 | 1565 | 0.090 |
Why?
|
Maternal Nutritional Physiological Phenomena | 1 | 2013 | 395 | 0.080 |
Why?
|
Treatment Outcome | 7 | 2024 | 65371 | 0.080 |
Why?
|
Rupture | 1 | 2011 | 444 | 0.080 |
Why?
|
Prenatal Care | 1 | 2017 | 1162 | 0.080 |
Why?
|
Health Care Costs | 2 | 2024 | 3239 | 0.080 |
Why?
|
Reverse Transcriptase Polymerase Chain Reaction | 3 | 2009 | 4580 | 0.080 |
Why?
|
Regional Blood Flow | 1 | 2012 | 1500 | 0.080 |
Why?
|
Parathyroidectomy | 1 | 2011 | 244 | 0.080 |
Why?
|
Infant | 5 | 2024 | 36535 | 0.080 |
Why?
|
Anticoagulants | 1 | 2024 | 4852 | 0.080 |
Why?
|
Calcinosis | 1 | 2017 | 1481 | 0.080 |
Why?
|
Tuberculosis | 1 | 2021 | 2029 | 0.080 |
Why?
|
Cross-Sectional Studies | 7 | 2024 | 26379 | 0.080 |
Why?
|
Fetal Growth Retardation | 1 | 2012 | 592 | 0.080 |
Why?
|
alpha 1-Antitrypsin | 1 | 2009 | 169 | 0.070 |
Why?
|
Cystatins | 1 | 2008 | 55 | 0.070 |
Why?
|
Age Factors | 3 | 2012 | 18412 | 0.070 |
Why?
|
Heart Function Tests | 1 | 2009 | 317 | 0.070 |
Why?
|
Health Personnel | 1 | 2022 | 3385 | 0.070 |
Why?
|
Chronic Disease | 3 | 2013 | 9384 | 0.070 |
Why?
|
Acute-Phase Proteins | 1 | 2009 | 252 | 0.070 |
Why?
|
Macrophage Activation | 1 | 2010 | 557 | 0.070 |
Why?
|
Receptors, Interleukin-6 | 1 | 2009 | 224 | 0.070 |
Why?
|
Graft Rejection | 2 | 2011 | 4492 | 0.070 |
Why?
|
Oxidoreductases | 1 | 2009 | 410 | 0.070 |
Why?
|
Intensive Care Units | 1 | 2021 | 3800 | 0.070 |
Why?
|
Primary Health Care | 1 | 2024 | 4746 | 0.070 |
Why?
|
Nephrectomy | 1 | 2012 | 930 | 0.070 |
Why?
|
Cost Sharing | 2 | 2020 | 409 | 0.070 |
Why?
|
Mortality | 1 | 2018 | 2911 | 0.070 |
Why?
|
Population Surveillance | 1 | 2017 | 2596 | 0.070 |
Why?
|
Retrospective Studies | 9 | 2024 | 81762 | 0.070 |
Why?
|
Calcium | 1 | 1999 | 5792 | 0.070 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2009 | 710 | 0.070 |
Why?
|
Retinoblastoma Protein | 1 | 2009 | 671 | 0.060 |
Why?
|
Research | 1 | 2014 | 1979 | 0.060 |
Why?
|
Practice Guidelines as Topic | 2 | 2020 | 7454 | 0.060 |
Why?
|
Tissue Donors | 1 | 2015 | 2381 | 0.060 |
Why?
|
Signal Transduction | 1 | 2009 | 23645 | 0.060 |
Why?
|
Atrial Fibrillation | 1 | 2024 | 5176 | 0.060 |
Why?
|
Pregnancy Complications | 2 | 2024 | 2973 | 0.060 |
Why?
|
Fibrinogen | 1 | 2009 | 891 | 0.060 |
Why?
|
Quality of Life | 2 | 2024 | 13490 | 0.060 |
Why?
|
Energy Intake | 2 | 2010 | 2146 | 0.060 |
Why?
|
Oceania | 1 | 2024 | 21 | 0.060 |
Why?
|
Costs and Cost Analysis | 2 | 2020 | 1667 | 0.060 |
Why?
|
Young Adult | 4 | 2024 | 60066 | 0.060 |
Why?
|
Aluminum Compounds | 1 | 2024 | 56 | 0.060 |
Why?
|
Longitudinal Studies | 2 | 2022 | 14783 | 0.060 |
Why?
|
Caribbean Region | 1 | 2024 | 193 | 0.060 |
Why?
|
Syria | 1 | 2024 | 86 | 0.060 |
Why?
|
Oligonucleotide Array Sequence Analysis | 2 | 2011 | 3800 | 0.060 |
Why?
|
Middle East | 1 | 2024 | 233 | 0.060 |
Why?
|
Russia | 1 | 2024 | 386 | 0.060 |
Why?
|
Enema | 1 | 2004 | 141 | 0.050 |
Why?
|
Sudan | 1 | 2023 | 86 | 0.050 |
Why?
|
Hypertrophy, Left Ventricular | 1 | 2009 | 856 | 0.050 |
Why?
|
Latin America | 1 | 2024 | 416 | 0.050 |
Why?
|
Ukraine | 1 | 2023 | 151 | 0.050 |
Why?
|
Ultrasonography | 1 | 2016 | 6004 | 0.050 |
Why?
|
Weight Gain | 1 | 2013 | 2359 | 0.050 |
Why?
|
Chromones | 1 | 2003 | 148 | 0.050 |
Why?
|
Poisoning | 1 | 2024 | 252 | 0.050 |
Why?
|
Emergency Medical Services | 1 | 2014 | 1947 | 0.050 |
Why?
|
Liver Failure | 1 | 2005 | 252 | 0.050 |
Why?
|
Diabetic Nephropathies | 2 | 2008 | 973 | 0.050 |
Why?
|
Peritoneum | 1 | 2023 | 230 | 0.050 |
Why?
|
Ghana | 1 | 2023 | 333 | 0.050 |
Why?
|
Rats, Sprague-Dawley | 2 | 2012 | 8128 | 0.050 |
Why?
|
Plants, Medicinal | 1 | 2003 | 167 | 0.050 |
Why?
|
Curriculum | 1 | 2016 | 3782 | 0.050 |
Why?
|
Sequence Homology, Nucleic Acid | 2 | 2000 | 1057 | 0.050 |
Why?
|
Comorbidity | 2 | 2009 | 10590 | 0.050 |
Why?
|
Reactive Oxygen Species | 1 | 2009 | 2149 | 0.050 |
Why?
|
Child Development | 1 | 2013 | 2330 | 0.050 |
Why?
|
Catheters, Indwelling | 1 | 2023 | 436 | 0.050 |
Why?
|
Tea | 1 | 2003 | 290 | 0.050 |
Why?
|
Australasia | 1 | 2020 | 21 | 0.050 |
Why?
|
Orthopedic Procedures | 1 | 2011 | 1279 | 0.050 |
Why?
|
North America | 1 | 2024 | 1289 | 0.050 |
Why?
|
Ethical Analysis | 1 | 2020 | 41 | 0.040 |
Why?
|
Iatrogenic Disease | 1 | 2024 | 552 | 0.040 |
Why?
|
Middle Aged | 11 | 2024 | 223492 | 0.040 |
Why?
|
Paracrine Communication | 1 | 2002 | 278 | 0.040 |
Why?
|
Disease Models, Animal | 1 | 2020 | 18349 | 0.040 |
Why?
|
Genetic Predisposition to Disease | 2 | 2019 | 18065 | 0.040 |
Why?
|
Animals | 8 | 2020 | 169246 | 0.040 |
Why?
|
Withholding Treatment | 1 | 2024 | 620 | 0.040 |
Why?
|
Isoniazid | 1 | 2021 | 288 | 0.040 |
Why?
|
RNA, Catalytic | 1 | 1999 | 52 | 0.040 |
Why?
|
Transportation of Patients | 1 | 2020 | 177 | 0.040 |
Why?
|
Epidemiologic Methods | 1 | 2004 | 1328 | 0.040 |
Why?
|
Waiting Lists | 1 | 2024 | 779 | 0.040 |
Why?
|
Administrative Personnel | 1 | 2020 | 185 | 0.040 |
Why?
|
Models, Biological | 1 | 2015 | 9495 | 0.040 |
Why?
|
Prevalence | 2 | 2023 | 15869 | 0.040 |
Why?
|
Postoperative Complications | 1 | 2021 | 15832 | 0.040 |
Why?
|
Energy Metabolism | 1 | 2010 | 2907 | 0.040 |
Why?
|
Interleukin-6 | 1 | 2009 | 3228 | 0.040 |
Why?
|
Electrolytes | 1 | 1999 | 279 | 0.040 |
Why?
|
Kidney Tubules, Proximal | 1 | 2000 | 386 | 0.040 |
Why?
|
Granuloma | 1 | 2021 | 329 | 0.040 |
Why?
|
Gene Expression | 2 | 2009 | 7598 | 0.040 |
Why?
|
Fetus | 1 | 2006 | 1883 | 0.040 |
Why?
|
Haiti | 2 | 2010 | 553 | 0.040 |
Why?
|
Aged | 5 | 2024 | 171504 | 0.040 |
Why?
|
Cause of Death | 1 | 2009 | 3721 | 0.040 |
Why?
|
Membrane Glycoproteins | 1 | 2009 | 3711 | 0.040 |
Why?
|
Emergency Service, Hospital | 2 | 2024 | 7951 | 0.040 |
Why?
|
Glucosides | 1 | 2003 | 533 | 0.040 |
Why?
|
Body Mass Index | 2 | 2013 | 13053 | 0.040 |
Why?
|
Urogenital Abnormalities | 1 | 2020 | 255 | 0.040 |
Why?
|
Syndrome | 1 | 2024 | 3272 | 0.040 |
Why?
|
Health Occupations | 1 | 2019 | 225 | 0.040 |
Why?
|
Diet | 2 | 2009 | 8089 | 0.040 |
Why?
|
Quality-Adjusted Life Years | 1 | 2024 | 1741 | 0.030 |
Why?
|
Constipation | 1 | 2002 | 570 | 0.030 |
Why?
|
Chemokine CCL2 | 1 | 1999 | 605 | 0.030 |
Why?
|
Biopsy | 1 | 2009 | 6793 | 0.030 |
Why?
|
Vesico-Ureteral Reflux | 1 | 2020 | 433 | 0.030 |
Why?
|
Patient Advocacy | 1 | 2019 | 362 | 0.030 |
Why?
|
Myocardium | 1 | 2009 | 4788 | 0.030 |
Why?
|
Gene Expression Profiling | 2 | 2011 | 9538 | 0.030 |
Why?
|
Risk Assessment | 1 | 2017 | 24315 | 0.030 |
Why?
|
Echocardiography | 1 | 2009 | 5047 | 0.030 |
Why?
|
Carrier Proteins | 1 | 2009 | 4937 | 0.030 |
Why?
|
Liver Diseases | 1 | 2004 | 1305 | 0.030 |
Why?
|
Suicide, Attempted | 1 | 2024 | 1409 | 0.030 |
Why?
|
Cells, Cultured | 2 | 2009 | 19015 | 0.030 |
Why?
|
Canada | 1 | 2020 | 2130 | 0.030 |
Why?
|
Renin-Angiotensin System | 1 | 1999 | 737 | 0.030 |
Why?
|
Stroke Volume | 1 | 2009 | 5622 | 0.030 |
Why?
|
In Situ Hybridization | 1 | 1998 | 1903 | 0.030 |
Why?
|
Attention Deficit Disorder with Hyperactivity | 1 | 2010 | 3729 | 0.030 |
Why?
|
Base Sequence | 3 | 2000 | 12421 | 0.030 |
Why?
|
Competency-Based Education | 1 | 2016 | 226 | 0.030 |
Why?
|
Biomedical Technology | 1 | 2016 | 210 | 0.030 |
Why?
|
Diabetes Mellitus, Experimental | 1 | 1999 | 1124 | 0.030 |
Why?
|
Acute Disease | 1 | 2024 | 7243 | 0.030 |
Why?
|
Feasibility Studies | 1 | 2024 | 5315 | 0.030 |
Why?
|
Antitubercular Agents | 1 | 2021 | 1397 | 0.030 |
Why?
|
RNA, Messenger | 3 | 2011 | 12800 | 0.030 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2004 | 10760 | 0.030 |
Why?
|
Congresses as Topic | 1 | 2017 | 812 | 0.020 |
Why?
|
Phenylephrine | 1 | 2012 | 292 | 0.020 |
Why?
|
Drug Evaluation, Preclinical | 1 | 2017 | 1338 | 0.020 |
Why?
|
Evidence-Based Practice | 1 | 2016 | 500 | 0.020 |
Why?
|
Caregivers | 1 | 2023 | 2302 | 0.020 |
Why?
|
Prospective Studies | 3 | 2024 | 54926 | 0.020 |
Why?
|
Maps as Topic | 1 | 2010 | 18 | 0.020 |
Why?
|
Neopterin | 1 | 2010 | 58 | 0.020 |
Why?
|
Severity of Illness Index | 1 | 2009 | 15948 | 0.020 |
Why?
|
Reproducibility of Results | 1 | 2009 | 20227 | 0.020 |
Why?
|
Choline | 1 | 2012 | 522 | 0.020 |
Why?
|
Kidney Glomerulus | 2 | 2006 | 570 | 0.020 |
Why?
|
Serum Amyloid A Protein | 1 | 2010 | 128 | 0.020 |
Why?
|
Aging | 1 | 2009 | 8744 | 0.020 |
Why?
|
Education, Medical, Continuing | 1 | 2016 | 829 | 0.020 |
Why?
|
Hospitals | 1 | 2024 | 3886 | 0.020 |
Why?
|
Molecular Sequence Data | 2 | 2000 | 17622 | 0.020 |
Why?
|
Antibodies, Viral | 1 | 2022 | 3216 | 0.020 |
Why?
|
Cohort Studies | 2 | 2024 | 41754 | 0.020 |
Why?
|
Obesity | 1 | 2012 | 13090 | 0.020 |
Why?
|
Endothelium, Vascular | 1 | 2002 | 4427 | 0.020 |
Why?
|
Chile | 1 | 2010 | 258 | 0.020 |
Why?
|
Calorimetry, Indirect | 1 | 2010 | 176 | 0.020 |
Why?
|
Models, Genetic | 1 | 1999 | 3447 | 0.020 |
Why?
|
Drug Discovery | 1 | 2017 | 1068 | 0.020 |
Why?
|
Body Weight | 1 | 1999 | 4627 | 0.020 |
Why?
|
Survival Analysis | 1 | 2021 | 10101 | 0.020 |
Why?
|
Quality Improvement | 1 | 2024 | 3857 | 0.020 |
Why?
|
Registries | 1 | 2024 | 8375 | 0.020 |
Why?
|
Societies, Medical | 1 | 2020 | 3968 | 0.020 |
Why?
|
HIV Infections | 2 | 2005 | 17569 | 0.020 |
Why?
|
Immunosuppressive Agents | 1 | 2020 | 4206 | 0.020 |
Why?
|
Mice, Transgenic | 1 | 1999 | 9561 | 0.020 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2024 | 10399 | 0.020 |
Why?
|
Diabetes Mellitus | 1 | 2005 | 5889 | 0.020 |
Why?
|
Survival Rate | 2 | 2011 | 12840 | 0.020 |
Why?
|
Apoptosis | 1 | 2002 | 9523 | 0.020 |
Why?
|
Oligosaccharides | 1 | 2008 | 407 | 0.020 |
Why?
|
Patient-Centered Care | 1 | 2016 | 1444 | 0.020 |
Why?
|
Kidney Function Tests | 1 | 2008 | 684 | 0.020 |
Why?
|
Anthropometry | 1 | 2010 | 1346 | 0.020 |
Why?
|
Genotype | 1 | 1999 | 13045 | 0.010 |
Why?
|
Immunohistochemistry | 1 | 1998 | 11095 | 0.010 |
Why?
|
Rest | 1 | 2010 | 948 | 0.010 |
Why?
|
Education, Medical | 1 | 2016 | 1742 | 0.010 |
Why?
|
Nitric Oxide | 1 | 2012 | 2146 | 0.010 |
Why?
|
International Cooperation | 1 | 2010 | 1436 | 0.010 |
Why?
|
Education, Medical, Graduate | 1 | 2016 | 2420 | 0.010 |
Why?
|
Magnetic Resonance Imaging | 1 | 2011 | 36743 | 0.010 |
Why?
|
Eating | 1 | 2010 | 1542 | 0.010 |
Why?
|
Incidence | 1 | 2021 | 21538 | 0.010 |
Why?
|
Reference Values | 1 | 2010 | 4938 | 0.010 |
Why?
|
Transplantation, Homologous | 1 | 2011 | 4833 | 0.010 |
Why?
|
Culture Media, Serum-Free | 1 | 2002 | 148 | 0.010 |
Why?
|
Phenotype | 1 | 1999 | 16726 | 0.010 |
Why?
|
Cytoprotection | 1 | 2002 | 200 | 0.010 |
Why?
|
Clinical Trials as Topic | 1 | 2017 | 8054 | 0.010 |
Why?
|
LLC-PK1 Cells | 1 | 2000 | 125 | 0.010 |
Why?
|
Biological Factors | 1 | 2002 | 156 | 0.010 |
Why?
|
Culture Media, Conditioned | 1 | 2002 | 521 | 0.010 |
Why?
|
Body Composition | 1 | 2010 | 2462 | 0.010 |
Why?
|
Prognosis | 2 | 2011 | 30010 | 0.010 |
Why?
|
Clinical Competence | 1 | 2016 | 4858 | 0.010 |
Why?
|
Receptor, Angiotensin, Type 2 | 1 | 1999 | 61 | 0.010 |
Why?
|
Vomiting | 1 | 2003 | 655 | 0.010 |
Why?
|
Follow-Up Studies | 2 | 2011 | 39348 | 0.010 |
Why?
|
Chromatography, High Pressure Liquid | 1 | 2003 | 1534 | 0.010 |
Why?
|
Predictive Value of Tests | 1 | 2015 | 15454 | 0.010 |
Why?
|
Receptor, Angiotensin, Type 1 | 1 | 1999 | 153 | 0.010 |
Why?
|
Xenopus | 1 | 2000 | 711 | 0.010 |
Why?
|
C-Reactive Protein | 1 | 2010 | 3858 | 0.010 |
Why?
|
Molecular Structure | 1 | 2003 | 1883 | 0.010 |
Why?
|
Enalapril | 1 | 1999 | 317 | 0.010 |
Why?
|
DNA, Complementary | 1 | 2000 | 1989 | 0.010 |
Why?
|
Growth Substances | 1 | 1999 | 759 | 0.010 |
Why?
|
Protein Kinase C | 1 | 2002 | 1207 | 0.010 |
Why?
|
United States | 1 | 2024 | 73039 | 0.010 |
Why?
|
Mass Spectrometry | 1 | 2003 | 2202 | 0.010 |
Why?
|
Rats, Wistar | 1 | 1999 | 1888 | 0.010 |
Why?
|
Cloning, Molecular | 1 | 2000 | 4168 | 0.010 |
Why?
|
DNA Primers | 1 | 1999 | 2828 | 0.010 |
Why?
|
Neovascularization, Physiologic | 1 | 2002 | 1369 | 0.010 |
Why?
|
Biphenyl Compounds | 1 | 1999 | 1026 | 0.010 |
Why?
|
Benzimidazoles | 1 | 1999 | 864 | 0.010 |
Why?
|
Time Factors | 1 | 2015 | 40218 | 0.010 |
Why?
|
Tetrazoles | 1 | 1999 | 923 | 0.010 |
Why?
|
Blood Glucose | 1 | 2008 | 6430 | 0.010 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 1 | 1999 | 1515 | 0.010 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 1999 | 1065 | 0.010 |
Why?
|
Magnetic Resonance Spectroscopy | 1 | 2003 | 3780 | 0.010 |
Why?
|
Mice | 1 | 1999 | 82029 | 0.010 |
Why?
|
Case-Control Studies | 1 | 2010 | 22291 | 0.010 |
Why?
|
Cell Survival | 1 | 2002 | 5777 | 0.010 |
Why?
|
Tumor Suppressor Protein p53 | 1 | 2002 | 2954 | 0.010 |
Why?
|
Enzyme Inhibitors | 1 | 2002 | 3728 | 0.010 |
Why?
|
Swine | 1 | 2000 | 5995 | 0.010 |
Why?
|
Amino Acid Sequence | 1 | 2000 | 13421 | 0.000 |
Why?
|
Mitochondria | 1 | 2002 | 3681 | 0.000 |
Why?
|
Macrophages | 1 | 1999 | 5799 | 0.000 |
Why?
|
Cytokines | 1 | 1999 | 7453 | 0.000 |
Why?
|